SecBot SecBot
SECBOTREPLAY Home › Report › ARMP

ARMP · Armata Pharmaceuticals appointed Dr

Armata Pharmaceuticals, Inc. · 8-K filed Apr 27, 2026 at 07:10 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Apr 27, 2026 at 07:10 ET

Armata Pharmaceuticals appointed Dr. Daniel Gilmer, a biopharmaceutical commercial executive with experience at Pfizer and McKinsey, to its Board of Directors. The move adds expertise in commercialization of anti-infectives, including leadership in the U.S. launch of PAXLOVID, to support Armata's development of bacteriophage therapeutics.

  • Dr. Daniel Gilmer, Ph.D., appointed to Board of Directors effective April 24, 2026
  • Gilmer previously served as Senior Director, Commercial Quality U.S. Team Lead at Pfizer since February 2025
  • He led the U.S. launch of PAXLOVID and has experience in commercial strategy, patient access, and antimicrobial resistance
  • Gilmer is an equal co-inventor on the patent for Exebacase, a first-in-class bacteriophage lysin

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access